Selank clinical trials: what the research actually shows

Last updated 2026-07-26

What clinical trials have actually been done on selank?

Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s, as a synthetic analog of tuftsin, an immunomodulatory peptide fragment of IgG ^[1]. The bulk of its clinical testing happened in Russia between the mid-1990s and roughly 2015, published in Russian-language journals like Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (Korsakov Journal of Neurology and Psychiatry) and Eksperimental'naya i Klinicheskaya Farmakologiya (Experimental and Clinical Pharmacology). The human studies generally fall into two buckets: trials in patients with generalized anxiety disorder (GAD) or neurotic/anxiety-spectrum conditions, and smaller studies looking at cognitive or stress-related endpoints in healthy volunteers. Sample sizes in the published trials tend to run from about 40 to 100 patients per study, which is small by Western regulatory standards but not unusual for early-phase Russian CNS drug development ^[2]. There is no selank trial registered on ClinicalTrials.gov as a completed Phase I-III program submitted to FDA, and no EMA assessment report exists. If you search for selank clinical trials expecting the same registry infrastructure you'd find for an SSRI or benzodiazepine, you won't find it. That absence is the single most important thing to understand before reading anything else about this compound. For readers who want the mechanism and background first, the selank overview page covers what the peptide is and how it's thought to work before you get into trial specifics.

How strong is the Russian clinical evidence, really?

The honest answer: it's real pharmacology research, done by credentialed institutions, but it does not meet the bar Western regulators require for drug approval, and almost none of it has been independently replicated outside Russia. Selank is registered as a prescription anxiolytic in Russia, approved by the Russian Ministry of Health, and sold there as a nasal spray under that indication. Russian regulatory approval is not the same thing as FDA approval. Russia's drug approval pathway historically required less extensive trial data than the US New Drug Application process, and Russian pharmacopeial studies are rarely powered or blinded to the standard a Phase III FDA trial would need. A drug can be legitimately approved and prescribed in Russia while still lacking the kind of evidence base that would get it through a US IND-to-NDA pipeline. The studies that do exist show consistent directional effects: reduced anxiety scores on scales like the Hamilton Anxiety Rating Scale (HAM-A), changes in EEG patterns consistent with anxiolytic activity, and some biochemical markers (serotonin and dopamine metabolite shifts, effects on the enzyme that breaks down enkephalins) suggesting a real central nervous system effect rather than placebo response alone ^{[2] [3]}. But most of these trials report limited detail on randomization method, blinding procedure, and dropout handling, the details a meta-analyst needs to grade study quality using GRADE or Cochrane risk-of-bias tools. Nobody has published a Cochrane review on selank, which itself tells you how thin the internationally indexed evidence base is. So: real research, real institutions, some real biological plausibility. Not FDA-grade evidence. Both things are true at once, and any article that tells you only one half is selling you something.

What did the anxiety trials in GAD patients find?

The most cited selank clinical work looked at patients with generalized anxiety disorder or anxiety-related adjustment disorders, using HAM-A score reduction as the primary outcome. A commonly referenced study (Zozulya et al., published in Russian psychiatric literature in the 2000s) reported that intranasal selank at doses around 3mg produced measurable HAM-A score reductions over 2 to 4 weeks of dosing, with effect onset reported as faster than typical for benzodiazepine-free anxiolytics, and without the sedation profile associated with benzodiazepines ^[2]. A separate strand of research examined selank's effect on enkephalin-degrading enzymes, proposing that selank works partly by slowing the breakdown of the body's own enkephalins (endogenous opioid-like peptides involved in stress response), rather than acting as a direct receptor agonist the way a benzodiazepine does ^[3]. This is presented as a plausible mechanism, not a proven one; the enzyme-inhibition data comes mostly from animal and in vitro work, with human corroboration limited. What's missing from essentially every one of these trials: a large multi-center design, a pre-registered protocol, an independent statistical review, and follow-up outside Russia. If you're used to reading FDA trial data with n=300+ per arm, adverse event tables broken out by MedDRA code, and a public FDA review document, the selank literature will feel thin by comparison. It is thin by comparison. That doesn't mean the effect isn't real; it means the confidence interval on 'how real, how big, how durable' is wide.

Are there any studies on selank for cognitive performance or focus?

Yes, but fewer than for anxiety, and they lean more toward stress-resilience and attention endpoints than pure 'nootropic' claims like memory consolidation. Some Russian studies looked at selank's effects on cognitive function under stress conditions, including in models of experimentally induced emotional stress, and reported improved task performance and reduced stress-hormone markers relative to control ^{[2] [4]}. This is a meaningful distinction from selank's sibling peptide, semax. Semax was developed by the same Russian research group and shares structural lineage (both derive from ACTH-related and related peptide research), but semax has a more developed track record specifically in stroke recovery and cognitive/neuroprotective indications, including registered use in Russia for post-stroke rehabilitation and ischemic conditions ^[5]. Selank's clinical focus, by contrast, sits more squarely in anxiety and stress modulation, with cognitive effects reported mostly as secondary or downstream of reduced anxiety and stress reactivity, not as a primary memory-enhancement claim. If your interest is specifically nootropic effects rather than anxiety relief, it's worth reading the semax vs selank comparison, since people frequently conflate the two peptides' evidence bases and they are not interchangeable.

What's the difference in evidence quality between selank and semax?

Semax has a somewhat larger and more clinically focused evidence base for specific neurological indications (particularly ischemic stroke and cognitive impairment after cerebrovascular events), while selank's literature clusters more around anxiety, stress, and immune-modulatory effects tied to its tuftsin lineage ^{[1] [5]}. Neither has completed Western regulatory trials. | Factor | Selank | Semax |

Were the selank studies randomized and placebo-controlled?

Some were, at least nominally, but the level of methodological detail published falls well short of what a Western regulatory submission requires. Several Russian trials describe comparison against placebo or against a reference anxiolytic, and report p-values for HAM-A reduction, but the published papers (often short-form journal articles rather than full trial reports) don't always disclose the randomization sequence generation, allocation concealment method, or a CONSORT-style flow diagram ^{[2] [3]}. This matters because 'randomized' and 'well-randomized-and-reported' are different claims. A trial can be randomized in practice while the publication simply doesn't give you enough to independently verify blinding integrity or check for selective outcome reporting. That's the situation with most of the selank literature: plausible methodology, incomplete reporting by modern standards, no independent audit. No peer-reviewed meta-analysis pooling selank RCTs exists in major English-language databases as of this writing, which is itself informative. When a compound has a genuinely deep, well-reported trial base, it tends to accumulate systematic reviews. Selank hasn't, at least not yet, in indexed Western literature.

Has selank been tested outside Russia, in the US or EU?

Not in registered human clinical trials. There's some Western-published animal and mechanistic research referencing selank (rodent anxiety models, biochemical pathway studies), but no Phase I-III program has been run under FDA IND or EMA clinical trial authorization frameworks ^[1]. This is the core reason selank is sold in the US as a research chemical rather than as an approved drug or supplement. The FDA has not evaluated selank for safety or efficacy for any human indication, and it holds no FDA-approved use ^[6]. Any US vendor selling it for human consumption without that context is skipping the part of the story you actually need. If a product's marketing implies FDA backing or 'clinically proven' status without naming the actual trials, treat that as a red flag, not reassurance.

What adverse effects showed up in the trials?

The published Russian trials report a generally favorable tolerability profile relative to benzodiazepines, with the most commonly noted issues being mild and transient: nasal irritation from intranasal dosing, occasional mild headache, and infrequent reports of drowsiness ^[2]. Researchers reported no evidence of the sedation, motor impairment, or dependence potential associated with benzodiazepine anxiolytics, which is part of why selank was pursued as an alternative anxiolytic mechanism in the first place. But 'no serious adverse events in trials of ~100 patients over a few weeks' is a much weaker safety claim than what exists for approved anxiolytics with decades of post-marketing surveillance across millions of patients. Rare adverse events, long-term effects, and interaction risks are essentially unstudied. If you want the fuller breakdown of documented and theoretical risks, the selank side effects page goes through what's actually been reported versus what's simply unknown.

What doses were used in the clinical studies?

Most Russian anxiety trials used intranasal selank in the range of roughly 250 micrograms to 3 milligrams per day, often split into two to three administrations, over treatment courses lasting 1 to 4 weeks ^[2]. This intranasal route matches how selank is registered and sold in Russia as a nasal spray. Dosing protocols used in the underlying trials don't automatically translate to safe or effective self-administered dosing outside a clinical protocol, particularly since research-chemical selank sold in the US is not manufactured or verified to pharmaceutical-grade nasal spray standards. If you're trying to understand actual dosing ranges people research today, including how they diverge from the original trial protocols, the selank dosage page and the selank semax injection page cover route-of-administration specifics in more depth than a trials-focused article should.

Why hasn't selank gone through FDA trials if the Russian data looks promising?

A few overlapping reasons, none of which are unique to selank. First, cost: a full FDA IND-to-NDA pipeline for a novel CNS peptide easily runs into hundreds of millions of dollars, and someone has to want to fund it, usually a pharmaceutical company betting on a patentable, marketable product. Second, patent and commercial incentive: selank's composition of matter dates back decades, which shrinks the commercial runway a company would have to recoup trial costs before generic competition. Third, regulatory philosophy: Russia's approval pathway historically accepted a different evidentiary bar than FDA's, so a compound can clear the Russian bar without ever being pushed through the far more expensive Western one. None of that proves selank doesn't work. It proves that the economic and regulatory machinery that produces Western-grade trial data for a compound like this hasn't been built. That's a market and incentive story as much as a science story, and it's worth holding both facts in your head at once when you're deciding how much weight to put on the existing research.

So how should you actually weigh the selank evidence?

Treat it the way you'd treat any promising but early-stage foreign clinical literature: real signal, real institutional research, but not equivalent to an FDA-reviewed drug, and not something you should assume is risk-free just because Russian regulators approved it decades ago. The practical takeaways: the anxiety-reduction signal across multiple small Russian trials is fairly consistent directionally ^{[2] [3]}, the tolerability profile reported in those trials looks better than benzodiazepines on paper, and essentially none of it has been replicated by an independent Western research group or reviewed by FDA or EMA ^{[1] [6]}. If you're going to use selank at all, sourcing from a provider that's transparent about exactly this evidence gap, rather than one that markets it as 'clinically proven,' matters more than almost anything else in the decision. Selank Co reviews providers with that transparency standard in mind, and where a fulfilling pharmacy partner is involved, names it rather than obscuring the supply chain. If your read on the anxiety literature makes you want to understand risk before dosage, start with selank side effects. If you're trying to decide between selank and semax for a specific goal (anxiety versus cognitive/stroke-adjacent use), the semax vs selank comparison is the more useful next read than another trials summary.

Frequently asked questions

Is selank FDA approved?

No. Selank has no FDA-approved use for any human indication. It's approved as a prescription anxiolytic nasal spray by Russia's Ministry of Health, but Russian approval does not equal FDA approval, and no selank compound has completed a registered FDA Phase I-III trial program ^[3][7].

How many clinical trials have been done on selank?

There's no single central registry count, but the published literature includes roughly a dozen or so identifiable Russian clinical studies from the 1990s through the 2010s, mostly small (40-100 patients), covering GAD, anxiety-spectrum disorders, and some stress/cognitive endpoints ^[1][2][4].

Are the selank studies peer reviewed?

Yes, most were published in peer-reviewed Russian medical journals like the Korsakov Journal of Neurology and Psychiatry and Experimental and Clinical Pharmacology. Peer review in that system doesn't guarantee the same reporting rigor Western journals now require (CONSORT, pre-registration), so peer-reviewed and rigorously-reported aren't the same claim here ^[2].

Does selank have any studies in English-language journals?

Some mechanistic and animal-model research on selank has appeared in English-language or internationally indexed journals, but the core human clinical trial data remains largely published in Russian-language sources, which limits independent Western scrutiny and citation tracking ^[1].

What's the difference between selank and semax in terms of research?

Selank's trial base centers on anxiety and stress; semax's centers more on stroke recovery and cognitive impairment, with a somewhat longer track record in Russian neurology. Neither has FDA or EMA trial data. See semax vs selank for the full comparison.

Can selank cause side effects based on the trials?

Reported trial-era side effects were generally mild: nasal irritation, occasional headache, rare drowsiness. Trials were small and short (weeks, not years), so rare or long-term effects are essentially undocumented. Details are on the selank side effects page.

Is there a Cochrane review or meta-analysis on selank?

No. As of this writing there's no Cochrane review or major indexed meta-analysis pooling selank RCTs, which reflects both the small number of trials and the limited methodological reporting available for pooling.

Why isn't selank tested in the US if it works in Russia?

Mainly economics and regulatory incentive: an FDA trial pipeline costs hundreds of millions of dollars, selank's composition of matter is decades old (weak patent runway), and Russia's approval pathway already let it reach market there without that investment.

What dose was used in the Russian anxiety trials?

Most trials used intranasal selank around 250 micrograms to 3 milligrams daily, split across two to three doses, for treatment courses of roughly 1 to 4 weeks ^[2][3]. See selank dosage for how this compares to commonly discussed self-administered ranges.

Does selank's mechanism have human confirmation or just animal data?

Partially both. Human trials show anxiolytic effects and some biochemical marker changes; the proposed enkephalin-degrading-enzyme mechanism is better documented in animal and in vitro work than confirmed directly in humans ^[4].

Is selank the same thing as semax?

No. They're related peptides from the same Russian research lineage but structurally different (selank derives from tuftsin/IgG, semax from ACTH) with different primary indications and separate trial histories. See selank vs semax.

Who developed selank and where was it studied?

Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, with clinical study conducted primarily at Russian research and psychiatric institutions from the 1990s onward ^[1].

Sources

1. Kolomin et al., 'Ligand of tuftsin, a heptapeptide selank' (background/mechanism), Institute of Molecular Genetics RAS-linked research: Selank is a synthetic tuftsin analog developed as an anxiolytic peptide with immunomodulatory background
2. Zozulya et al., clinical study of selank in anxiety disorders, Eksperimental'naya i Klinicheskaya Farmakologiya: Selank produced HAM-A anxiety score reductions in clinical study with reported favorable tolerability
3. Medvedev et al., biochemical mechanism of selank action on enkephalin-degrading enzymes: Selank's proposed mechanism involves inhibition of enkephalin-degrading enzymes rather than direct receptor agonism
4. Kozlovskaya et al., selank effects on emotional stress and cognitive performance: Selank showed effects on stress-related cognitive performance markers in experimental models
5. Semax pharmacological review, stroke and neuroprotection research: Semax has a distinct clinical history focused on stroke recovery and cognitive/neuroprotective indications
6. U.S. Food and Drug Administration, FDA-approved drug listing and approval process overview: No selank product has completed FDA's drug development and approval process